Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for riluzole

  1. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)

    Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).

    Technology appraisal guidance
    Published
    23 January 2001
    View recommendations

    Sections for TA20

  2. Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date:  17 March 2027

    Highly specialised technologies guidance
    In development

  5. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

    NICE guideline
    Last updated
    23 July 2019
    View recommendations

    Sections for NG42

  6. Past appeals and decisions

    Past technology appraisal appeals and decisions